 SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 GLOBE NEWSWIRE -- Eliem Therapeutics, Inc. Nasdaq: ELYM, a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliems president and chief executive officer, will present at Stifels 2022 CNS Days being held virtually on Tuesday, March 29, 2022 at 9:30 AM ET. 